Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Buys $15,150.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson bought 1,000 shares of the business’s stock in a transaction dated Friday, August 2nd. The shares were bought at an average cost of $15.15 per share, for a total transaction of $15,150.00. Following the purchase, the vice president now directly owns 262,348 shares in the company, valued at approximately $3,974,572.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jaye Thompson also recently made the following trade(s):

• On Thursday, July 18th, Jaye Thompson acquired 1,000 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $16,000.00.

Greenwich LifeSciences Trading Down 3.3 %

Shares of GLSI stock opened at $13.71 on Thursday. The company’s fifty day moving average price is $15.53 and its 200-day moving average price is $14.32. The stock has a market cap of $176.58 million, a PE ratio of -19.04 and a beta of 1.64. Greenwich LifeSciences, Inc. has a 12 month low of $7.58 and a 12 month high of $21.44.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings data on Monday, May 20th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. On average, sell-side analysts forecast that Greenwich LifeSciences, Inc. will post -0.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Greenwich LifeSciences in a research note on Wednesday, May 22nd.

Institutional Trading of Greenwich LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in GLSI. Rhumbline Advisers purchased a new stake in shares of Greenwich LifeSciences in the second quarter worth $117,000. Bank of New York Mellon Corp bought a new stake in Greenwich LifeSciences during the 2nd quarter valued at about $264,000. Finally, Vanguard Group Inc. raised its holdings in Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after buying an additional 1,420 shares during the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.